期刊文献+

磷酸西格列汀的合成工艺改进 被引量:5

Improved synthesis of sitagliptin phosphate
原文传递
导出
摘要 目的改进磷酸西格列汀的合成方法。方法以2,4,5-三氟苯乙酸为原料,经缩合、水解得到3-氧代-(2,4,5-三氟苯基)丁酸甲酯,该甲酯与手性苯乙胺反应,经硼氢化钠还原,再经缩合、脱保护、成盐得到磷酸西格列汀。结果与结论提供了一条简捷高效且适合工业化生产磷酸西格列汀的工艺路线,7步反应的总收率为39.5%。关键还原步骤以廉价的硼氢化钠为还原剂,使本工艺避免了使用有毒、昂贵试剂,符合绿色化学的原则。 An improved synthesis of sitagliptin phosphate w as reported in this paper. The key enamine intermediate 6 w as prepared from starting material 2,4,5-trifluorophenyl acetic acid( 2) via condensation w ith M eldrum 's acid,methanolysis under room temperature and condensation w ith α-phenethylamine 6,diastereoseletive reduction by Na BH4 under mild condition to give chiral amine,w hich w as aminolyzed in the presence of DIPEA to give intermediate 8. The title product sitagliptin phosphate w as afforded from 8 via deprotection and salification in isopropyl alcohol( IPA). The procedure enclosed here w as an efficient and economical route to a practical synthesis of stagliptin phosphate( 39. 5% yield in 7 steps). The use of Na BH4,as a cheap reducing reagent avoided expensive and toxic reagents,which followed the principles of green chemistry.
出处 《中国药物化学杂志》 CAS CSCD 2015年第5期382-385,共4页 Chinese Journal of Medicinal Chemistry
关键词 西格列汀 2型糖尿病 合成 工艺改进 sitagliptin type 2 diabetes synthesis process improvement
  • 相关文献

参考文献14

  • 1许菁,王玉丽,徐为人,张士俊.治疗2型糖尿病的新型药物——西他列汀[J].中国药物与临床,2007,7(11):861-863. 被引量:8
  • 2XIAO Yi, JOSEPH D, KRSKA S W, et al. Process for the preparation of chiral beta amino acid deriva-fives by asymmetric hydrogenation :WO ,2004085378 [ P]. 2004 - 03 - 15.
  • 3DREHER S D, IKEMOTO N, NIOLITO E, et al. Process to chiral /3-amino acid derivatives: WO, 2004085661 [ P]. 2004 - 10 - 07.
  • 4PADI P R, IRENI B, POLAVARAPU S, et al. Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof: WO, 2009085990 [ P ]. 2009 - 07 - 09.
  • 5孙桂芳,蔡正艳,周伟澄.西他列汀合成路线图解[J].中国医药工业杂志,2008,39(5):383-386. 被引量:12
  • 6王建塔,张毅,朱高峰,毛远湖,汤磊.磷酸西他列汀的合成[J].中国医药工业杂志,2011,42(8):561-564. 被引量:4
  • 7KIM D,WANG L P,BECONI M. (2R)-4-E3-(Trif- luorornethyl) -5,6-dihydro I 1,2,4 ] triazolo E 4,3-a ] pyrazin-7 (8H) -yl] -1- (2,4,5-trifluoromethyl) butan- 2-amine:a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[ J]. J IVied Chem,2005,48( 1 ) :141 -151.
  • 8KUBRYK M, HANSEN K B. Application of the asymmetric hydrogenation of enarnines to the prepa- ration of a/3-amino acid plaarmacophore [ J ]. Tetra- hedron: Asymmetry, 2006,17 (2) : 205 - 209.
  • 9SUN Piao-yang, CHEN Yong-jiang, YU Guang-liang. Process for preparing R-fl-anfino phenylbutyric acid derivatives: US,8580997[ P]. 2013 - 11 - 12.
  • 10LIN Kuai-le, CAI Zheng-yan, ZHOU Wei-cheng. Practical and economical approach to synthesize sita- gliptin [ J ]. Synth Commun, 2013,43 ( 24 ) : 3281 - 3286.

二级参考文献41

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 2Kim D, Wang LP, Beconi M. (2R)-4-Oxo-4-[3- (trifluoromethyl) -5,6-dihydro [ 1,2,4] triazolo [4,3-a] pyrazin- 7 (8H) -yl] -1- (2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J]. J Med Chem, 2005, 48 (1) : 141-151.
  • 3Hansen KB, Balsells J, Dreher S, et al. First generation process for the preparation of the DPP-IV inhibitor sitagliptin [J]. Org Process Res Dev, 2005, 9 (5) : 634-639.
  • 4Dreher SD, Ikemoto N, Niolito E, et al. Process to chiral β-amino acid derivatives: WO, 2004085661 [P]. 2004-10-07. (CA 2004, 141: 332476).
  • 5肖毅,阿姆斯特隆三世JD,克尔斯卡SW,等.通过不对称氢化来制备手性β-氨基酸衍生物的方法:中国,1761642[P].2007-09-26.
  • 6Kubryk M, Hansen KB. Application of the asymmetric hydrogenation of enamines to the preparation of a β-amino acid pharmacophore [J]. Tetrahedron Asymm, 2006, 17 (2) : 205-209.
  • 7King SA, Thompson AS, King AO, et al. An improved procedure for the synthesis and use of [RuCI2 (BINAP) ] 2.NEt3. Dependence of the Ru ( Ⅱ ) - B1NAP catalyzed asymmetric hydrogenation of !3-keto esters on trace amounts of acid [J]. J Org Chem, 1992, 57 (25): 6689-6691.
  • 8Zhu Y, Xia S, Zhu M, et al. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase 1V inhibitors [J]. Eur J Med Chem, 2010, 45 ( 11 ) : 4953-4962.
  • 9Gallwitz B.Therapies for the treatment of type 2 diabetes mellitus based on incretinaction.Minerva Endocrinol,2006,31(2):133-147.
  • 10Ahren B,Landin-olsson M,Jansson PA,et al.Inhibition of dipeptidyl peptidase-4 reduces glycemia,sustains insulin levels,and reduces glucagon levels in type 2 diabetes.J Clin Endocrinol Metab,2004,89(5):2078-2084.

共引文献19

同被引文献26

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部